Longitudinal analysis of Epstein-Barr viral load in plasma and peripheral blood mononuclear cells of transplanted patients by real-time polymerase chain reaction12
Authors:
- Lars FischerLFLars Fischer
- Wolfram J. JabsWJWolfram J. Jabs
- Meike HolbeMHMeike Holbe
- Klaus PethigKPKlaus Pethig
- Peter BucskyPBPeter Bucsky
- 1 September 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 74 (5) , 656-664
Abstract
Posttransplant lymphoproliferative disease (PTLD) is a significant cause of morbidity and mortality in transplant recipients and is caused by iatrogenic suppression of T cell function. Elevations in the Epstein-Barr viral (EBV) load in plasma (>1000 EBV copies/100 μL plasma) or peripheral blood mononuclear cells (PBMC) (>5000 EBV copies/μg PBMC DNA) as determined by real-time quantitative polymerase chain reaction (RQ-PCR) have been shown to be sensitive indicators for the development of PTLD in patients. The diagnostic value of frequent monitoring of EB viral load in peripheral blood from 46 patients after heart transplantation was investigated compared with 21 healthy controls in a prospective longitudinal study. EB viral load was detected in PBMC and plasma using real-time quantitative (RQ)- polymerase chain reaction (PCR)-based assays and compared with serological parameters of EBV infection or with the occurrence of CMV reactivations. EB viral load was significantly increased in PBMC and in plasma from transplanted patients compared with healthy controls. Regarding levels and fluctuations of EB viral load in PBMC, patients were grouped in three distinct categories with high, intermediate, or low EB viral load. Although in one patient without PTLD, the EB viral load exceeded the threshold value for PTLD of 5000 EBV copies/μg PBMC DNA, all patients had an EB viral load in plasma of less than 1000 EBV copies/100 μL plasma. No correlation was found between the level of EB viral load and serological parameters of EBV reactivations in patients or in healthy control individuals. EBV and cytomegalovirus reactivations occurred independently in the majority of patients. EB viral load measurements in plasma and PBMC of patients using RQ-PCR are superior to serology and are a powerful tool for monitoring transplanted patients.Keywords
This publication has 26 references indexed in Scilit:
- PATIENTS AT RISK FOR DEVELOPMENT OF POSTTRANSPLANT LYMPHOPROLIFERATIVE DISORDER: PLASMA VERSUS PERIPHERAL BLOOD MONONUCLEAR CELLS AS MATERIAL FOR QUANTIFICATION OF EPSTEIN-BARR VIRAL LOAD BY USING REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION1,2Transplantation, 2001
- Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patientsBlood, 2001
- Normalized Quantification by Real-Time PCR of Epstein-Barr Virus Load in Patients at Risk for Posttransplant Lymphoproliferative DisordersJournal of Clinical Microbiology, 2001
- Characterization of Epstein-Barr virus–infected B cells in patients with posttransplantation lymphoproliferative disease: disappearance after rituximab therapy does not predict clinical responseBlood, 2000
- Epstein–Barr Virus InfectionNew England Journal of Medicine, 2000
- Quantitative Molecular Analysis of Virus Expression and ReplicationJournal of Clinical Microbiology, 2000
- Clinical and pathological features of post-transplant lymphoproliferative disorders (PTLD)Springer Seminars in Immunopathology, 1998
- EPSTEIN-BARR VIRUS DNA IN PERIPHERAL BLOOD LEUKOCYTES OF PATIENTS WITH POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASETransplantation, 1995
- Increased levels of circulating Epstein-Barr virus (EBV)-infected lymphocytes and decreased EBV nuclear antigen antibody responses are associated with the development of posttransplant lymphoproliferative disease in solid-organ transplant recipientsBlood, 1994
- Direct correlation between the load of Epstein-Barr virus-infected lymphocytes in the peripheral blood of pediatric transplant patients and risk of lymphoproliferative diseaseBlood, 1994